GlassScriptPhysician profile
David W Suetholz
NPI 1811950256
$1,439.20
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $721 · 2020: $299 · 2021: $419.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $253.33 | 2019-2021 | |
| Abbvie INC. | $195.13 | 2021 | |
| Biodelivery Sciences International, INC. | $156.99 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $142.83 | 2020-2021 | |
| Indivior INC. | $135.74 | 2019-2021 | |
| Horizon Therapeutics Plc | $125.63 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $121.75 | 2020-2021 | |
| Lilly USA, LLC | $75.85 | 2020-2021 | |
| Novo Nordisk INC | $50.87 | 2020-2021 | |
| Orexo US, INC. | $47.37 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $30.07 | 2019 | |
| Pfizer INC. | $25.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.16 | 2019 | |
| Mdd US Operations, LLC | $13.65 | 2019 | |
| Amgen INC. | $13.21 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $13.07 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.95 | 2019 | |
| Daiichi Sankyo INC. | $10.76 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Suetholz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.